Your browser doesn't support javascript.
loading
Coagulation, Protease-Activated Receptors, and Diabetic Kidney Disease: Lessons from eNOS-Deficient Mice.
Oe, Yuji; Miyazaki, Mariko; Takahashi, Nobuyuki.
Affiliation
  • Oe Y; Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine.
  • Miyazaki M; Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine.
  • Takahashi N; Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences & Faculty of Pharmaceutical Sciences.
Tohoku J Exp Med ; 255(1): 1-8, 2021 09.
Article in En | MEDLINE | ID: mdl-34511578
ABSTRACT
Endothelial nitric oxide synthase (eNOS) dysfunction is known to exacerbate the progression and prognosis of diabetic kidney disease (DKD). One of the mechanisms through which this is achieved is that low eNOS levels are associated with hypercoagulability, which promotes kidney injury. In the extrinsic coagulation cascade, the tissue factor (factor III) and downstream coagulation factors, such as active factor X (FXa), exacerbate inflammation through activation of the protease-activated receptors (PARs). Recently, it has been shown that the lack of or reduced eNOS expression in diabetic mice, as a model of advanced DKD, increases renal tissue factor levels and PAR1 and 2 expression in their kidneys. Furthermore, pharmaceutical inhibition or genetic deletion of coagulation factors or PARs ameliorated inflammation in DKD in mice lacking eNOS. In this review, we summarize the relationship between eNOS, coagulation, and PARs and propose a novel therapeutic option for the management of patients with DKD.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Receptors, Proteinase-Activated / Diabetic Nephropathies / Nitric Oxide Synthase Type III Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: Receptors, Proteinase-Activated / Diabetic Nephropathies / Nitric Oxide Synthase Type III Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2021 Type: Article